TMC is pleased to announce that tranScrip, a specialist pharmaceutical consultancy, is now part of the TMC Group.
The acquisition brings together two highly accomplished, multidisciplinary teams with a shared commitment to helping emerging biotech and pharma companies progress therapies from innovative science to patients.
Established in 2001, TMC is a global pharma services company operating across hubs in the UK, US and EU (Ireland) and through its vast network of global contractors in over 70 countries. TMC offers end-to-end drug development solutions, from early-phase consulting and clinical development to market access and drug commercialisation. With over 20 years’ experience and a strong reputation, tranScrip’s expert medical, clinical and regulatory solutions complement TMC’s existing services.
By combining these capabilities, TMC can better support emerging pharma and biotech companies across the full product lifecycle — with broader regulatory, medical and scientific expertise, plus greater access to specialist subject-matter experts and increased capacity for complex programmes.
On the news, Simon Estcourt, CEO of TMC, said: “We are pleased to welcome tranScrip into TMC. Throughout our discussions, we have been consistently impressed by the depth of expertise and the strength of client relationships across the business. The combination strengthens our ability to support clients throughout the development lifecycle while creating new opportunities for growth and collaboration.”
Simon joined TMC as CEO in 2024 and has spearheaded this latest phase in its development to take the company to new heights.